Navigating The Evolving Advanced Therapy Regulatory Landscape With Accuracy, Efficiency, And Expertise

Scientist Using Pipette GettyImages-1140779660

The development and approval process for cell and gene therapies pose additional complexities compared to more traditional therapeutics. Regulatory approval tends to focus more on the production process itself, and chemistry, manufacturing, and controls (CMC) are particularly impactful due to factors such as shorter shelf life, variability in starting and ancillary materials, manufacturing and logistical complexities, and cost.

In this case study, a biopharmaceutical company focused on developing novel autologous T cell therapies had promising findings targeting a rare-disease tumor type and filed all of the necessary components for their Investigational New Drug (IND) application. However, the FDA indicated that there was insufficient data within the drug master file. Review the submission process and regulatory expertise which helped the biopharmaceutical company avoid a clinical hold and advance to phase 1 clinical trials.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene